Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $49.25 which represents a decrease of $-0.05 or -0.10% from the prior close of $49.3. The stock opened at $49.35 ...

Halozyme is relatively low-beta and an ideal stock in the biotech sector for a covered call trade with good liquidity on ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...

On Monday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $51.77 which represents a decrease of $-0.84 or -1.60% from the prior close of $52.61. The stock opened at $52.6 ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new targets under its global collaboration and license agreement ...

SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a ...